Q-omics provides the consensus-scored PNMA6E profile across patient tissues and cancer cell-line models. PNMA6E expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PNMA6E is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, PNMA6E RNA expression shows 6,278 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight LUAD, BRCA, and PRAD as cancer lineages where PNMA6E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA6E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA6E survival associations across molecular data types. PNMA6E RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA6E RNA expression–survival associations across cancer types. High PNMA6E expression shows unfavorable associations in LUSC, KIRP and ESCA, but favorable associations in LUAD, BLCA and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for PNMA6E RNA expression.
This table summarizes PNMA6E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PNMA6E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA6E shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA and HNSC. The BRCA box plot shows higher PNMA6E RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p = .028).
This table shows molecular features associated with PNMA6E in patient tissues and cancer cell lines. In patient samples, PNMA6E shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA6E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
